GlaxoSmithKline plc (LON:GSK) insider Victoria Whyte sold 5,199 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of GBX 1,295 ($17.89), for a total transaction of £67,327.05 ($93,018.86).

Shares of GlaxoSmithKline plc (LON:GSK) opened at GBX 1,291 ($17.84) on Wednesday. GlaxoSmithKline plc has a fifty-two week low of GBX 1,235.20 ($17.07) and a fifty-two week high of GBX 1,724.50 ($23.83). The stock has a market cap of $64,010.00 and a PE ratio of 4,164.52.

The company also recently declared a dividend, which will be paid on Thursday, April 12th. Stockholders of record on Thursday, February 22nd will be issued a GBX 23 ($0.32) dividend. This represents a dividend yield of 1.78%. This is an increase from GlaxoSmithKline’s previous dividend of $19.00. The ex-dividend date is Thursday, February 22nd.

Several research firms recently weighed in on GSK. Deutsche Bank restated a “hold” rating and set a GBX 1,440 ($19.89) price target on shares of GlaxoSmithKline in a research report on Thursday, February 8th. Credit Suisse Group set a GBX 1,300 ($17.96) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a report on Thursday, February 8th. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline in a report on Thursday, February 8th. Berenberg Bank dropped their price objective on shares of GlaxoSmithKline from GBX 1,760 ($24.32) to GBX 1,705 ($23.56) and set a “buy” rating on the stock in a report on Thursday, February 8th. Finally, Barclays reaffirmed an “overweight” rating and set a GBX 1,650 ($22.80) price objective on shares of GlaxoSmithKline in a report on Friday, February 9th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of GBX 1,540.45 ($21.28).

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/14/glaxosmithkline-plc-gsk-insider-sells-67327-05-in-stock.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.